Neuroendocrine Tumor Unit, Endocrinology and Metabolism Department, Division of Medicine, Hadassah-Hebrew University Medical Center, P.O.B. 12000, 91120, Jerusalem, Israel.
ENETS Center of Excellence, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Rev Endocr Metab Disord. 2021 Sep;22(3):553-561. doi: 10.1007/s11154-020-09624-y. Epub 2021 Jan 14.
Carcinoid heart disease (CHD) is a paraneoplastic cardiac manifestation occurring in patients with carcinoid syndrome (CS) and advanced neuroendocrine malignancy. In about 20-40% of patients with CS, chronic exposure to tumor-released circulating vasoactive peptides typically results in right-sided valvular fibrosis leading to valve dysfunction and right heart failure. CHD remains a significant cause of morbidity and mortality. The management of patients with CHD is complex, as both the systemic malignant disease and the heart involvement have to be addressed. Early diagnosis and timely surgical intervention in selected patients are of utmost importance and offer a survival benefit. In patients with advanced carcinoid heart disease, valve replacement surgery is the most effective option to alleviate cardiac symptoms and contribute to survival outcomes. A collaboration of a multidisciplinary team in centers with experience is required to provide optimal patient management. Here, we review the current literature regarding CHD presentation, pathophysiology, diagnostic tools, and available treatment strategies.
类癌心脏疾病(CHD)是一种副瘤性心脏表现,发生于类癌综合征(CS)和晚期神经内分泌恶性肿瘤患者中。在约 20-40%的 CS 患者中,慢性暴露于肿瘤释放的循环血管活性肽通常导致右侧瓣膜纤维化,导致瓣膜功能障碍和右心衰竭。CHD 仍然是发病率和死亡率的重要原因。CHD 患者的管理非常复杂,因为必须同时处理系统性恶性疾病和心脏受累。早期诊断和及时的手术干预对选定的患者至关重要,并带来生存获益。在晚期类癌心脏疾病患者中,瓣膜置换手术是缓解心脏症状和改善生存结果的最有效选择。需要有经验的多学科团队合作,以提供最佳的患者管理。在此,我们综述了关于 CHD 表现、病理生理学、诊断工具和现有治疗策略的当前文献。